Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Hopital Necker Enfants MaladesParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06228352
- Record updated
- 24 June 2026
- Original description
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease characterized by chronic inflammation of the colon. Composition of gut microbiota of UC patients is abnormal (dysbiosis).Read full original descriptionShow less
Is Clostridioides Difficile Infection Associated With Changes in Bile Acid Profiles in Children With Ulcerative Colitis
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease characterized by chronic inflammation of the colon. Composition of gut microbiota of UC patients is abnormal (dysbiosis).
Ulcerative Colitis patients have an increased risk of Clostridioides difficile infection (CDI) and CDI complications (colectomy, death, recurrence). The reason for this increased risk in IBD patients is not fully understood. The decrease in the proportion of secondary bile acids, induced by microbiota dysbiosis in patients with UC could favor C. difficile infection.
The main objective of the study is to describe the composition of bile acids (primary and secondary) in children followed for UC during relapse with or without CDI and to compare it to children with UC in remission and healthy controls. The composition of fecal microbiota will be also describe to correlate dysbiosis and bile acid abnormalities. And finally some fecal biomarkers will be study : short chain fatty acids, metabolic pathway of Tryptophan, and fecal Calprotectin.
Inclusion: Pediatric patients (<18 years) consultant or hospitalized in the Gastroenterology department of Necker-Enfants Malades Hospital; Information and consent of parents and the patient; Patient with UC, whatever the extent, except isolated proctitis (<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria; UC in flare defined by a PUCAI score of between 35 and 65; Non-inclusion criteria:; Patient with IBD unclassified or Crohn's disease; Patient with isolated proctitis (<5 cm); Colectomized patients; Patients with sclerosing cholangitis associated with their UC or liver disease; Group 2: Patients in UC remission; Patient with UC, whatever the extent, except isolated proctitis (<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria; UC in remission defined by a PUCAI score <10; Non-inclusion criteria:; Patient with IBD unclassified or Crohn's disease; Patient with isolated proctitis (<5 cm); Colectomized patients; Patients with sclerosing cholangitis associated with their UC or liver disease; Group 3: Healthy control subjects; Patients hospitalized for an endoscopic assessment to control for abdominal pain, gastroesophageal reflux or polyposis; Non-inclusion criteria:; Patient with chronic liver disease; Patient with chronic digestive disease (celiac disease, IBD, chronic chronic).
Exclusion: Patient who received antibiotic or antifungal treatment in the 4 weeks prior to inclusion; Patients colonized by C. difficile; Pregnant or breastfeeding young girl; Refusal of the protocol by parents or patient; For group 1: Patients with active UC.
For everyone :.